HK Stock Market Move | BYD COMPANY (01211) rose more than 3%, with sales reaching 480,000 vehicles in November, setting a new high for the year.

10:35 02/12/2025

BYD Company (01211) rose more than 3%, as of press time, up 3.32% to 101.2 Hong Kong dollars, with a turnover of 1.194 billion Hong Kong dollars.

BYD COMPANY (01211) rose more than 3%, reaching 3.32% at the time of publication, at 101.2 Hong Kong dollars, with a turnover of 1.194 billion Hong Kong dollars. On the news side, on the evening of December 1st, BYD Company Limited disclosed that it sold 480,186 vehicles in November, setting a new high for the year. From January to November 2025, BYD Company Limited sold 4.18 million cars, an increase of 11.3% year-on-year. In addition, the total installed capacity of new energy vehicle power batteries and energy storage batteries for BYD Company Limited in November 2025 was approximately 27.669GWh, and the cumulative installed capacity in 2025 was approximately 258.282GWh. Daiwa Securities previously stated in a research report that BYD Company Limited has optimized its cost structure to match production layout with market demand, allowing it to maintain competitiveness in different regulatory and economic environments.

HK Stock Market Move | Yankuang Energy Group (01171) rose by nearly 3% recently, with its subsidiary planning to acquire all equity of a high-end bracket company for 3.45 billion yuan.

HK Stock Market Move | HIGHTIDE-B(02511) rose by over 6%, and the positive results of the HTD1801 compared head-to-head with Dapagliflozin Phase III clinical trial.

HK Stock Market Move | VISEN PHARMA-B (02561) rises by over 12% again, Longyou growth hormone is about to be approved. The company recently reached a strategic cooperation agreement with Tofflon Science and Technology Group.

HK Stock Market Move | Yankuang Energy Group (01171) rose by nearly 3% recently, with its subsidiary planning to acquire all equity of a high-end bracket company for 3.45 billion yuan.

HK Stock Market Move | HIGHTIDE-B(02511) rose by over 6%, and the positive results of the HTD1801 compared head-to-head with Dapagliflozin Phase III clinical trial.